Skip to main
VRDN
VRDN logo

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Viridian Therapeutics (VRDN) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 40%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Viridian Therapeutics is positioned for a positive financial outlook due to its innovative product, Veligrotug, which shows promising clinical results in treating thyroid eye disease, including proptosis reduction and improvement in patient quality of life. The company's development of VRDN-003 for subcutaneous administration is expected to enhance its market presence and competitive advantage, leading to increased market share in the therapy for thyroid eye disease. Furthermore, successful clinical execution and regulatory progress are anticipated to boost investor confidence and support potential commercial launches, driving future growth and valuation increases.

Bears say

The financial outlook for Viridian Therapeutics Inc. is considerably negative due to the potential delays in the launch of its lead product candidate, Veligrotug, which could result in a valuation decrease of approximately $4 per share if postponed by a year. Additionally, the risk of ineffective results from the REVEAL studies could remove VRDN-003 from estimates, leading to a substantial $14 per share reduction and reflecting a 30% downside risk to the company. Compounding these challenges, the threat of competition from well-capitalized industry players along with concerns related to intellectual property protection and management execution further diminishes Viridian's market positioning and long-term profitability prospects.

Viridian Therapeutics (VRDN) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 40% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viridian Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viridian Therapeutics (VRDN) Forecast

Analysts have given Viridian Therapeutics (VRDN) a Buy based on their latest research and market trends.

According to 10 analysts, Viridian Therapeutics (VRDN) has a Buy consensus rating as of Dec 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viridian Therapeutics (VRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.